Comparative Study of Efficacy and Safety of Rocuronium Bromide with Suxamethonium Chloride for Tracheal Intubation

Background: Tracheal intubation is a cornerstone of modern anesthetic practice, with neuromuscular blocking agents playing a critical role. Among these agents, Suxamethonium chloride is widely used for its quick onset and brief duration. However, its associated side effects have prompted the search for alternatives like Rocuronium Bromide, a non-depolarizing agent known for its rapid onset, intermediate duration, and minimal adverse effects. The study aims to compare the effectiveness and safety of Suxamethonium chloride and Rocuronium Bromide. It evaluates their onset times, intubating conditions, duration of action, hemodynamic effects, and adverse reactions. Materials and Methods: A randomized trial was conducted with 110 patients divided into two groups. Group A received Suxamethonium (1.5 mg/kg IV), and Group B was administered Rocuronium (0.9 mg/kg IV). Observations were made on intubation quality, onset timing, and hemodynamic changes. Results: Group A exhibited faster onset and superior intubating conditions (100% excellent scores) compared to Group B (87.3% excellent scores). However, Rocuronium demonstrated longer duration of action, hemodynamic stability, with significantly lower postoperative heart rate and blood pressure fluctuations. Additionally, Group B had no reported adverse effects, while Group A experienced 12.7% postoperative myalgia. Conclusion: Rocuronium represents a safer alternative for tracheal intubation, with enhanced hemodynamic stability and fewer side effects, despite slightly less favorable intubating conditions than Suxamethonium.